Pages that link to "Q42167248"
Jump to navigation
Jump to search
The following pages link to Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder (Q42167248):
Displaying 9 items.
- Lithium monotherapy increases ACTH and cortisol response in the DEX/CRH test in unipolar depressed subjects. A study with 30 treatment-naive patients (Q28478124) (← links)
- Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study (Q31028649) (← links)
- Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms (Q31156853) (← links)
- Relative hypo- and hypercortisolism are both associated with depression and lower quality of life in bipolar disorder: a cross-sectional study (Q33763259) (← links)
- Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder (Q34180109) (← links)
- Role of lithium augmentation in the management of major depressive disorder (Q38192967) (← links)
- Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression (Q44309148) (← links)
- General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. (Q51509688) (← links)
- [Twenty-five years of lithium augmentation] (Q80215518) (← links)